期刊文献+

含异噁唑环的药物先导化合物的设计、合成与活性研究

Development of the Studies on the Design, Synthesis and Bio-Activity of Isoxazole-contained Derivatives
原文传递
导出
摘要 本文综述了将取代异噁唑作为药效活性基团,引入到四类不同母体分子中,所合成的新型化合物分别具有抗菌、消炎等生物活性,成为有价值的药物先导化合物的研究进展。 Isoxazole derivatives have been used as key intermediates in synthesis and have been investigated intensively for the last several years because of their biological activities. In this review, isoxazole ring was introduced into the four types of different molecules as substituent, the designed compounds were synthesized with multi-steps and the structures of the formed new compounds were confirmed by NMR, MS and IR etc. Preliminary bio-tests showed that some of the compounds exhibited interesting properties as anti-biotics and anti-inflammatory agents.
出处 《世界科技研究与发展》 CSCD 2009年第5期787-792,共6页 World Sci-Tech R&D
基金 国家重大基础研究前期研究专项资助项目(2003CCA027) 山东省科技计划专项资助项目(032090104)
关键词 异嗯唑 合成 生物活性 先导化合物 isoxazole synthesis bio-activities lead compounds
  • 相关文献

参考文献38

  • 1Jose Luis Garcia Ruano. Cristina Fajardo and M. Rosario Martin. Synthesis of alkyl 4 - (diethoxymethyl) -3-pyridin-3 -ylisexazole-5-carboxylates :useful scaffold for highly functionalised 3-( pyridin-3-yl )isoxazoles [ J]. Tetrahedron ,2005,61:4363 - 4371.
  • 2耿亮,雷鸣,王彦广.异噁唑基取代的1,2,4-噁二唑啉和吡唑啉类化合物的合成[J].有机化学,2005,25(6):690-695. 被引量:6
  • 3Stanislav A Bakunov, Svetlana M Bakunova, E V K Suresh Kumar, et al. Synthesis and in vitro antiprotozoal activities of dicationic 3,5-diphenylisoxazoles[J]. J Med Chem,2007,50:2468 - 2485.
  • 4Henniger P W, Staid P M. 7 - [ 3-Substituted isoxazol-5 -yl ] -acetamidoephalo- sporanic acids and their anti-bacterial use[ P]. US4010264, Dec, 1974.
  • 5Adams J M. On the release of the formyl group from nascent protein [ J]. J Mol. Biol, 1968,33:571 - 589.
  • 6Livingston D M, Leder P. Deformylation and protein synthesis[J].Biochemistry, 1969,8:435 - 443.
  • 7Meinnel T, Blanquet S. Evidence that peptide deformylase and methionyl-tRNA(fMet) formyltransferase are encoded within the same operon in Escherichia coli [ J]. J Bacteriol, 1993,175:7737 - 7740.
  • 8Chan M K,Gong W M,Rajagopalan P T R,et al. Crystal structure of the escherichia coli peptide deformylase [ J]. Biochemistry, 1997,36 : 13904 - 13909.
  • 9Rajagopalan P T R, Yu X C, Pei D H. Peptide deformylase : a new type of mononuclear iron protein [ J ]. J Am Chem Soc, 1997,119 : 12418-12419.
  • 10Groche D, Becker A, Schlichting I, et al. Isolation and crystallization of functionally competent E. coli peptide deformylase forms containing either iron or nickel in the active site [ J ]. Biochem Biophys Res Commun, 1998,246:342 - 346.

二级参考文献60

  • 1张大同,贾炯,冯勇,王建武,徐为人,汤立达.肽脱甲酰化酶及其抑制剂研究进展[J].中国新药杂志,2005,14(5):530-534. 被引量:1
  • 2[1]Takeda S,Ishthara K, Wakui Y, et al. Bioavailability study ofglycyrrhetic acid after oral administration of glycyrrhizin in rats;relevance to the intestinal bacterial hydrolysis[J].J PharmPharmacol,1996, 48(9):902.
  • 3[2]Van Rossum TG, Vulto AG, De Man RA, et al. Review article:glycyrrhizinas a potential treatment for chron-ic hepatitis C[J].Aliment Pharmacol Ther, 1998, 12(2):199.
  • 4[3]Van Rossum TG, Vulto AG, Hop WC, et al.Intraveno-us glycyrrhizin for the treatment of chronic hepatitis C:a double-blind, randomized, placebo controlled pha-se I/II trial[J]. J Gastroenterol Hepatol,1999, 14(11):1 093.
  • 5[4]Yamamura Y, Kotaki H, Tanaka N, et al. The pharmaco-kinetics of glycyrrhizin and its restorative effect on he-patic function in patients with chronic hepatitis and in chronicallycarbon-tetrachloride-intoxicated rats[J].Biopharm Drug Dispos, 1997, 18(8):717.
  • 6[5]Yamamura Y, Santa T, Kotaki H, et al. Administrationroute dependency of absorption of glycyrrhizin in rat-
  • 7[6]s:intraperitoneal administration dramatically enhancedbioavailability[J]. Biol Pharm Bull, 1995,18(2):337.
  • 8[7]Okamoto T, Tanaka N, Vulto AG, et al. The protectiveeffect of glycyrrhizin on anti-fas antibody-inducedhepatitis in mice[J]. Eur J Pharmacol, 2000, 387(2):229.
  • 9[8]Okamoto T, Kanda T, Vulto AG, et al. Glycyrrhizin protects mice fromconcanavalin A-induced hepatitiswithout affecting cytokine expression[J]. Int J Mol M-ecl, 1999, 4(2):149.
  • 10[9]Tsabota A. Corrbinecl ursodeoxycholic acid and glycyrrhizin therapy forchronic hepatitis C virus infection:a randomized controlled trial in 170patients[J].Eur J Gastroenterd Hepatol, 1999, 11(10):1 077.

共引文献132

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部